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Abstract
Introduction Our aim was to develop consensus guidelines for
use of recombinant activated factor VII (rFVIIa) in massive
hemorrhage.
Methods A guidelines committee derived the recommendations
using clinical trial and case series data identified through
searches of available databases. Guidelines were graded on a
scale of A to E (with A being the highest) according to the
strength of evidence available. Consensus was sought among
the committee members for each recommendation.
Results A recommendation for the use of rFVIIa in blunt trauma
was made (grade B). rFVIIa might also be beneficial in post-
partum hemorrhage (grade E), uncontrolled bleeding in surgical
patients (grade E), and bleeding after cardiac surgery (grade D).
rFVIIa could not be recommended for use in the following: in
penetrating trauma (grade B); prophylactically in elective
surgery (grade A) or liver surgery (grade B); or in bleeding
episodes in patients with Child–Pugh A cirrhosis (grade B).
Efficacy of rFVIIa was considered uncertain in bleeding
episodes in patients with Child–Pugh B and C cirrhosis (grade
C). Monitoring of rFVIIa efficacy should be performed visually
and by assessment of transfusion requirements (grade E), while
thromboembolic adverse events are a cause for concern. rFVIIa
should not be administered to patients considered
unsalvageable by the treating medical team.
Conclusion There is a rationale for using rFVIIa to treat massive
bleeding in certain indications, but only adjunctively to the
surgical control of bleeding once conventional therapies have
failed. Lack of data from randomized, controlled clinical trials,
and possible publication bias of the case series data, limits the
strength of the recommendations that can be made.
Introduction
This study is endorsed by the European Society of Anaesthe-
siology (ESA), the European Society of Intensive Care Medi-
cine (ESICM), the European Society for Emergency Medicine
(EuSEM), the European Resuscitation Council (ERC), the
European Haematology Association (EHA) and the European
Association of Trauma and Emergency Surgery (EATES).
Uncontrolled massive hemorrhage is an important cause of
morbidity and mortality. In patients with traumatic injury, it is
second only to injuries to the central nervous system as the
most common cause of death in the prehospital setting [1,2],
and is the primary cause of early in-hospital (first 48 hours)
mortality due to trauma [3]. In patients with liver disease,
severe upper gastrointestinal (UGI) bleeding is fatal in about
FFP = fresh frozen plasma; OLT = orthotopic liver transplantation; PT = prothrombin time; RBCs = red blood cells; rFVIIa = recombinant activated 
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30% of cases [4], whereas in patients undergoing open heart
surgery, coagulopathic bleeding has been shown to increase
both morbidity and mortality [5].
Massive hemorrhage is often characterized by a surgical or
vascular component and a coagulopathic component. The sur-
gical/vascular component can be corrected by surgical inter-
vention or embolization. However, coagulopathic bleeding is
more difficult to control. Coagulopathy arises through several
interrelated mechanisms, which include the consumption of
coagulation factors and platelets through repeated attempts
to form clots during massive hemorrhage, the dilution of coag-
ulation factors as a result of fluid resuscitation, and metabolic
disorders (hypothermia or acidosis), which can affect the
coagulation process [6]. Together with acidosis and hypother-
mia, coagulopathy forms the so-called 'lethal triad' in trauma,
because of associated high mortality rates [7].
Conventional treatment options for coagulopathic/diffuse
bleeding include fluid replacement (crystalloids and colloids)
to maintain circulating volume, and the use of blood products
such as red blood cells (RBCs), fresh frozen plasma (FFP),
cryoprecipitate or fibrinogen, and platelets to replace the
blood components lost during hemorrhage. However,
attempts at resuscitation with large volumes of intravenous flu-
ids can lead to an exacerbation of coagulopathy and may fail
to arrest bleeding [8]. Furthermore, the use of blood products
is associated with an increase in the risk of infections [9] and
complications such as multiple organ failure and acute respi-
ratory distress syndrome [10], which may result in increased
mortality and morbidity [11,12].
The limitations of replacement therapy suggest the need for
additional approaches to the treatment of coagulopathic
bleeding. Hemostatic agents offer some promise as adjunctive
therapy to be used with current treatments, but there are lim-
ited clinical trial data. Recombinant activated factor VII (rFVIIa,
NovoSeven®; Novo Nordisk, Copenhagen, Denmark) may be
useful in the treatment of coagulopathic bleeding. However,
rFVIIa is currently approved worldwide only for the treatment
of bleeding in patients with hemophilia A or B with inhibitors to
coagulation factors VIII or IX [13]. In Europe, it is also
approved for factor VII deficiency and Glanzmann's throm-
basthenia in patients who are refractory to platelet transfu-
sions, but it is not currently approved as an adjunctive
treatment for massive or coagulopathic bleeding in any
country.
In cases of injury, tissue factor (TF) is brought into contact with
naturally occurring FVIIa, which is normally present in minute
quantities, to initiate the coagulation pathway [14,15]. At phar-
macological, supraphysiological doses, rFVIIa is able to bind
to activated platelets at the site of injury and activate factors IX
and X directly, leading to a thrombin burst [16]. As platelets
are activated only at sites of TF exposure, it is believed that the
action of rFVIIa is therefore localized to these sites. Neverthe-
less, a primary concern of treatment with rFVIIa is the possibil-
ity of an increased incidence of thrombotic adverse events,
arising from a systemic activation of the coagulation pathway
or from TF exposure at sites not associated with tissue injury,
such as unstable coronary plaques [17].
rFVIIa is increasingly being used on a compassionate use
basis [18]. However, there is no clear guidance on which
patients are suitable for treatment, the appropriate timing of
rFVIIa administration, and the most appropriate dose of rFVIIa
to use. Although there are several ongoing Phase III clinical tri-
als (see Additional file 1), the results will not be available for
several years. Guidelines might therefore help to ensure that
physicians receive appropriate guidance on the use of rFVIIa.
This might be important when considering the potential costs,
safety concerns and the risk of unpredictable adverse events,
as well as the risks of overuse or inappropriate use associated
with this treatment. In addition, published guidelines may help
to protect physicians from the suggestions of substandard
care when opting not to use rFVIIa in massive bleeding
because of the lack of formally approved indications, and may
also offer help with reimbursement when linked to the appro-
priate use of drugs not currently available on the open market.
This article presents a systematic review of the use of rFVIIa in
patients with major hemorrhage, together with key recommen-
dations for use based on these data. It is based on a consen-
sus developed by experts in the fields of critical care medicine,
anesthesia and intensive care medicine, emergency medicine,
trauma, and hematology, representing the major European
organizations, and is intended to assist the practicing physi-
cian in the appropriate use of this product.
Materials and methods
Suitable references to compile this guidelines publication
were identified from Medline, EMBASE and the Cochrane
reviews (1980 to 2005) by using the following search terms:
recombinant activated factor VII, recombinant factor VIIa,
recombinant FVIIa, rFVIIa, and NovoSeven®. These results
were cross-referenced with the terms trauma, coagulopathy,
haemorrhage/hemorrhage, uncontrolled bleeding, and sur-
gery. Additional searches were performed on recent clinical
studies, case series and review publications to identify poten-
tial references not identified via the electronic database
search.
The committee process began in July 2005 with initial elec-
tronic communications regarding structure, content and
scope of the guidelines. References identified through the lit-
erature search were also made available to the committee. A
meeting was held in September 2005 to assess the literature
and develop recommendations for treatment for each potential
rFVIIa indication. Clinical trial evidence supporting each rec-
ommendation was graded on the basis of a modified DelphiAvailable online http://ccforum.com/content/10/4/R120
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methodology with categorization, according to the criteria
described in Table 1[19]. Each clinical trial was graded
according to the presence or absence of key elements such
as concealed randomization, blinded outcome assessment,
intention-to-treat analysis, and explicit definition of a primary
outcome. A strict evidence-based methodology with a scoring
system was not used. The goal was total consensus among
the members of the committee, which was reached for all the
recommendations.
After the meeting in September, refinement of the recommen-
dations continued through electronic communications and tel-
ephone discussions. The document was finalized and




Massive bleeding is classically described as loss of 1 blood
volume in 24 hours. In the context of these recommendations,
we should consider greater loss of blood volumes, such as
loss of 50% blood volume in less than 3 hours. Under these
conditions, administration of blood products would precede
the administration of rFVIIa.
General recommendations
Recommendation 1. Every attempt should be made to control
bleeding by conventional means. rFVIIa should not replace
and/or delay surgery or any other methods used to control the
source of bleeding, such as angiography with embolization.
Grade E
Rationale 1. rFVIIa will be effective only once sources of major
bleeding (such as open blood vessels) have been closed.
Once major bleeding from damaged vessels has been
stopped, it may be helpful to induce coagulation in areas of dif-
fuse bleeding and oozing.
Recommendation 2. Traditional use of blood products, includ-
ing RBCs, platelets, FFP, and cryoprecipitate/fibrinogen,
should not be replaced by rFVIIa. Grade E
Rationale 2. rFVIIa is not a first-line treatment for bleeding. The
focus of treatment is still replacement therapy with blood prod-
ucts such as RBCs, FFP, platelets, and cryoprecipitate/fibrin-
ogen. rFVIIa should be considered only if first-line treatment
with a combination of blood products and surgical approaches
fails to control bleeding. However, it should be remembered
that for rFVIIa to promote coagulation, sufficient levels of plate-
lets and fibrinogen are required.
Recommendation 3. Every effort should be made to reduce
the effects of, or to achieve the correction of, factors that may
interfere with coagulation, including hypothermia, severe aci-
dosis, low hematocrit, and hypocalcemia. An attempt to
reverse the effects of any anticoagulant therapy should be
made when possible. Grade E
Rationale 3. Hypothermia and coagulopathy in trauma are cur-
rently poorly understood; in general, the greater the degree of
hypothermia, the greater the risk of uncontrolled bleeding.
When severe injury is associated with hypothermia and acido-
sis, mortality rates of up to 100% have been reported. The
Table 1
Grading of recommendations and evidence.
Grading of recommendations
A Supported by at least two level I investigations
B Supported by one level I investigation
C Supported by level II investigations only
D Supported by at least one level III investigation
E Supported by level IV and V evidence
Grading of evidence
I Large randomized trials with clear-cut results; low risk of false-positive (alpha) error or false-negative 
(beta) error
II Small randomized trials with uncertain results; moderate-to-high risk of false-positive (alpha) error and/
or false-negative (beta) error
III Nonrandomized, contemporaneous controls
IV Nonrandomized, historical controls and expert opinion
V Case series, uncontrolled studies, and expert opinionCritical Care    Vol 10 No 4    Vincent et al.
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effects of hypothermia include altered platelet function,
impaired coagulation factor function (a 1°C decrease in
temperature is associated with a 10% decrease in function),
enzyme inhibition, and fibrinolysis [20,21]. Body temperatures
below 34°C compromise blood coagulation, but this has been
observed only when coagulation tests (prothrombin time [PT]
and activated partial thromboplastin time) are performed at the
low temperatures seen in patients with hypothermia, and not
when assessed at 37°C (as is routine practice for such tests).
Although Meng and colleagues [22] have shown that correc-
tion of hypothermia is not necessary for the proper functioning
of rFVIIa, body temperature should be restored to as near
physiological levels as possible, because even small reduc-
tions in temperature can result in slower coagulation enzyme
kinetics [23].
In addition, coagulation disorders are aggravated by acidosis,
caused by inadequate tissue oxygen supply. Moreover, hypoc-
alcemia is frequently present in severely injured patients [24]
and may require the administration of intravenous calcium, fol-
lowed by frequent assessment to control serum levels of ion-
ized calcium.
Recommendation 4. If major bleeding persists despite the
above steps, the use of rFVIIa should be considered. To
ensure maximal rFVIIa efficacy, attempts should be made to
achieve the following: platelets more than 50,000 × 109/l;
fibrinogen 0.5 to 1.0 g/l; pH ≥ 7.20; hematocrit more than
24%. Grade E
Rationale 4. rFVIIa acts on the patient's own clotting system.
To ensure the formation of a stable clot, fibrinogen levels will
need to be maintained [25,26]. Furthermore, at pharmacolog-
ical (that is, supraphysiological) doses, rFVIIa triggers the
thrombin burst through direct binding to activated platelets;
sufficient platelets must therefore be available. A reduction in
platelet count also leads to impaired thrombin generation [27].
A recent study has shown that a pH of less than 7.10 will sub-
stantially reduce rFVIIa activity [22].
Recommendation 5. Before administering rFVIIa, the patient,
or the patient's next of kin, should be informed about the type
of treatment that they are receiving. Grade E
Rationale 5. Because rFVIIa is not approved for any of the indi-
cations discussed in this publication, the patient's next of kin
should be informed that rFVIIa is being used outside the cur-
rently approved indications (off-label use).
Control of overt bleeding
Trauma
Recommendation.  An initial dose of 200 µg/kg rFVIIa, fol-
lowed by two doses of 100 µg/kg, administered at 1 and 3
hours after the first dose, may reduce RBC transfusion require-
ments, the need for massive transfusion, and the incidence of
respiratory failure (acute respiratory distress syndrome) in
patients with blunt trauma [28]. Grade B
Recommendation. The effects of rFVIIa in patients with pene-
trating trauma are uncertain, and no recommendations can be
made for this indication. Grade B
Rationale. Several case studies and case series have shown
that treatment with rFVIIa can be beneficial in the treatment of
coagulopathic bleeding after trauma [29-31]. In a large US
case series (n = 81) in patients with coagulopathic bleeding
as a result of trauma and other causes, rFVIIa at doses of
between 40 and 150 µg/kg was successfully used to stop
bleeding in 75% of these cases [31]. A retrospective cohort
analysis of 29 patients treated with rFVIIa (initial dose 40 µg/
kg, with 52% of patients receiving a second dose) matched
with historical controls demonstrated significant reductions in
RBC, platelet and cryoprecipitate requirements in the rFVIIa
group with no increase in complications and a comparable
mortality rate [32].
Most recently, guidelines for rFVIIa use have been published,
based on findings from a case series of 36 patients who
received rFVIIa on a compassionate use basis in Israel [30].
Treatment with rFVIIa successfully stopped bleeding in 72%
of cases, leading the authors to recommend an initial dose of
120 µg/kg (between 100 and 140 µg/kg), with a second dose
if required. If bleeding continues, a third dose can be consid-
ered only if the patient's coagulation parameters are within an
acceptable range. The authors recognize the lack of any sup-
porting clinical trial data for these recommendations and sug-
gest that their dosing recommendations be taken as advisory.
Definitive recommendations on dosing require evidence from
prospective, randomized, controlled clinical trials, and until
recently this level of evidence was not available. The recently
completed multicenter, randomized, double-blind, placebo-
controlled study by Boffard and colleagues [28] examined the
efficacy of rFVIIa in patients with blunt or penetrating trauma.
Patients were randomized to receive either three doses of
rFVIIa (200, 100, and 100 µg/kg) or placebo after they had
received six units of RBCs, and received the first dose of their
assigned medication after transfusion of a further two units of
RBCs (eight in total), followed by a second and third dose, 1
and 3 hours after the initial dose. Treatment with rFVIIa pro-
duced a significant reduction in the primary endpoint, RBC
transfusion requirements (a surrogate for blood loss), and sig-
nificantly reduced the need for massive transfusions (more
than 20 units of RBCs [post hoc definition]) in patients with
blunt trauma surviving for more than 48 hours, and also signif-
icantly reduced the incidence of acute respiratory distress syn-
drome in all patients with blunt trauma.
Further support for the dose regimen recommended here
comes from pharmacokinetic modeling techniques, whichAvailable online http://ccforum.com/content/10/4/R120
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have shown that the dose regimen for rFVIIa treatment used in
these randomized trials is capable of providing adequate
plasma levels of drug to support hemostasis [33]. However, it
should also be pointed out that the target concentration (40 U/
ml) chosen in this study was based only on previous in vitro
studies and thus remains a matter of debate.
Therefore, although the 200 µg/kg dose should be recom-
mended, because it is the dose used in the only randomized
study available, it remains possible that lower doses might be
as efficient. Further studies are needed to answer this impor-
tant question. Moreover, if there is clinical evidence that coag-
ulopathy has been corrected by the first dose(s), there is no
evidence to support the systematic administration of subse-
quent doses.
Although it might be possible to discuss recommendations for
patients with blunt trauma, no recommendations are possible
for those with penetrating trauma. No significant effects were
seen on RBC transfusion requirements in these patients,
although trends towards reduced RBC requirements and
fewer massive transfusions were observed. In contrast to blunt
trauma, penetrating trauma may be more easily controlled
through surgical methods, and the level of bleeding is often
lower than in blunt trauma. In the patients with penetrating
trauma in this study, the reduced level of bleeding might have
decreased the power to detect reductions in blood loss, and
this might explain the lack of a significant reduction in RBC
requirements. The issue of how to select appropriate patients
to assess the effects of rFVIIa in penetrating trauma will need
to be addressed in future studies.
Liver disease
Recommendation. Based on the currently available evidence,
rFVIIa should not be used in patients with Child–Pugh A cir-
rhosis. Grade B
Recommendation. In patients with Child–Pugh B and C cir-
rhosis, the efficacy of rFVIIa in patients with bleeding episodes
(esophageal and UGI bleeding, and bleeding after percutane-
ous needle biopsy) is uncertain. Grade C
Rationale. A preliminary, single-center, dose-escalation study
in nonbleeding patients with advanced liver disease showed
that treatment with rFVIIa could normalize PT and might there-
fore be useful in the treatment of bleeding due to liver disease.
Ten patients with abnormal PT values were given three suc-
cessive dosages of rFVIIa (5, 20, and 80 µg/kg) over a 3-week
period. The mean PT was transiently corrected to normal in all
three dose groups [34].
A randomized, double-blind, placebo-controlled trial assessing
the efficacy and safety of rFVIIa in 245 cirrhotic patients with
variceal and nonvariceal UGI bleeding produced inconclusive
results. Patients were randomized to receive eight doses of
100 µg/kg rFVIIa or placebo, in addition to pharmacological
and endoscopic treatment. No overall effect of rFVIIa on the
primary composite endpoint (failure to control UGI bleeding
within 24 hours after first dose, or failure to prevent rebleeding
Figure 1
Algorithm for use of rFVIIa (see the text regarding rFVIIa dosing in different settings) Algorithm for use of rFVIIa (see the text regarding rFVIIa dosing in different settings). Hct, hematocrit; rFVIIa, recombinant activated factor VII.Critical Care    Vol 10 No 4    Vincent et al.
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between 24 hours and day 5, or death within 5 days) was
observed, and no significant differences were observed in
mortality. However, post hoc analyses in the subgroup of
Child–Pugh B and C cirrhotic patients indicated that adminis-
tration of rFVIIa may decrease the proportion of patients who
have failed to control variceal bleeding [35].
Post-partum hemorrhage
Recommendation. rFVIIa may be considered as a treatment for
life-threatening post-partum hemorrhage but should not be
considered as a substitute for, nor should it delay, the perform-
ance of a life-saving procedure such as embolization or sur-
gery, nor the transfer to a referring center. Grade E
Rationale. No randomized, controlled clinical studies investi-
gating rFVIIa use in patients with post-partum hemorrhage
have been performed. However, several individual case
reports have demonstrated that rFVIIa may be an effective
bleeding control in patients with severe post-partum hemor-
rhage [36-38]. A review of 13 cases of post-partum hemor-
rhage by Boehlen and colleagues [39] also demonstrates a
positive effect on bleeding for doses from as low as 17.5 µg/
kg to 120 µg/kg. A recent case series in 12 patients with
severe life-threatening post-partum hemorrhage treated at a
women's clinic in Helsinki over a 16-month period also
showed positive effects on bleeding after treatment with
rFVIIa. Doses ranging from 42 to 116 µg/kg were used and 11
out of 12 patients showed either a partial or a good response
in terms of the reduction in RBC/FFP/platelet transfusion
requirements [40]. However, these results should be inter-
preted with care, because of potentially serious publication
bias resulting from the likelihood that only successful cases
are reported.
Uncontrolled bleeding in surgical patients
Recommendation. There have been individual case reports of
the successful use of rFVIIa when all other standard measures
of bleeding control have failed. In the view of the panel, com-
mon sense would suggest that it might be prudent to consider
rFVIIa for surgical bleeding if all other options have been con-
sidered. Grade E
Rationale. No prospective, randomized clinical studies exam-
ining rFVIIa use in uncontrolled bleeding in surgical patients
have been published. Several case studies have documented
successful control of bleeding after administration of rFVIIa
(doses between 80 and 120 µg/kg) in surgical settings,
although such case studies may be subject to serious publica-
tion bias [41-51]. In cases where surgical bleeding is not con-
trolled by conventional means, common sense suggests that
rFVIIa may be considered, despite the potential for publication
bias.
Cardiac surgery
Recommendation. rFVIIa may be beneficial in controlling post-
operative bleeding after cardiac surgery. Grade D
Rationale. There are currently no data from prospective, rand-
omized, placebo-controlled clinical trials examining the effi-
cacy of rFVIIa in cardiac surgery, although there is currently
one ongoing clinical study (see Additional file 1). Small case
series and several case studies have reported the successful
use of rFVIIa in cardiac surgery. Several larger case series and
one small pilot, randomized, placebo-controlled clinical trial
have also reported beneficial effects of rFVIIa administration.
However, all case series and case studies reported here may
be subject to serious potential publication bias.
In a small randomized, placebo-controlled study, 20 patients
undergoing complex cardiac surgery were randomized to
receive rFVIIa or placebo after cardiopulmonary bypass. There
was a significant reduction in the risk of requiring allogeneic
RBCs and coagulation products in patients receiving rFVIIa in
comparison with patients who received placebo [52].
A case series comprising 51 patients treated for intractable
hemorrhage after cardiac surgery at a single center, with pro-
pensity-score-matched historical control patients from the
same center, showed that rFVIIa may be of benefit. Patients
received either 2.4 mg (44 patients) or 4.8 mg (7 patients) of
rFVIIa, with a second dose as required. Treatment with rFVIIa
significantly reduced requirements for transfusion of RBCs
and other blood products, and there was a marked and signif-
icant reduction in International Normalized Ratio, whereas a
small reduction in partial thromboplastin time was adjudged to
be clinically insignificant [53].
In a retrospective case series of 16 patients from a single
center who received rFVIIa after cardiac surgery, a mean dose
of 65 µg/kg rFVIIa (range 24 to 192 µg/kg) resulted in signifi-
cant reductions in both the volume of bleeding and the require-
ments for RBCs and FFP [54]. Similarly, a retrospective case
series in 24 patients from a single center with uncontrollable
life-threatening bleeding showed that a single rFVIIa dose of
60 µg/kg rFVIIa stopped or reduced bleeding in 18 out of 24
patients, whereas 5 patients required more than one dose. A
significant reduction in blood loss through chest drains was
also reported [55].
A case series of 40 patients from a single center included 24
patients with bleeding after cardiac surgery. Patients received
a 90 µg/kg rFVIIa dose, followed by a second dose 6 hours
later, if required. Twelve cardiac surgery patients (50%) died
within 4 hours of treatment, and the effects of treatment could
not be determined. In the 12 surviving patients, there were sig-
nificant reductions in RBC, FFP, platelet, and cryoprecipitate
requirements. Six of these remaining 12 patients survived toAvailable online http://ccforum.com/content/10/4/R120
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discharge, the remaining 6 dying between 3 and 30 days after
treatment [56].
A review of 20 cases of bleeding after cardiac bypass showed
that single or multiple doses of rFVIIa between 30 and 120 µg/
kg (mean dose 101 µg/kg) successfully restored hemostasis.
In 14 patients (70%), rapid hemostasis was achieved after a
single dose of rFVIIa (mean dose 57 µg/kg), whereas in the
remaining 6 patients, gradual hemostasis was achieved after a
mean of 3.4 doses (mean cumulative dose 225 µg/kg) [57].
In a retrospective cohort analysis of 24 patients treated with
rFVIIa (median initial dose 60 µg/kg, 42% of the patients
receiving a second dose and 8% a third dose), who were
matched with historical controls, blood loss and transfusion
requirements were significantly reduced in the period after
rFVIIa administration, but not after 24 hours. The requirement
for platelet concentrates was reduced in the rFVIIa group, but
6-month survival rates were not significantly different. No
thromboembolic complications were noted [58].
Prevention of bleeding
Elective surgery
Recommendation.  Prophylactic administration of rFVIIa in
elective surgical patients is currently not recommended.
Grade A
Rationale. In a recent double-blind, randomized, placebo-con-
trolled trial, rFVIIa administered prophylactically failed to con-
trol bleeding in patients with normal hemostasis undergoing
surgical repair of major traumatic fracture of the pelvis or the
pelvis and acetabulum who were expected to have a large vol-
ume of blood loss [59]. Patients received 90 µg/kg rFVIIa or
placebo as add-on therapy at the time of the first skin incision,
in addition to intraoperative salvaged RBCs. Treatment with
rFVIIa had no significant effect on the total volume of perioper-
ative blood loss, the primary outcome variable, between the
rFVIIa and placebo groups. Furthermore, there were no signif-
icant differences between the two groups in any transfusion
parameters, including the total volume of blood components,
the number of patients requiring allogeneic blood compo-
nents, or the total volume of fluids infused. However, there was
a significant reduction in postoperative blood loss (rFVIIa, 240
ml; placebo, 370 ml; p = 0.022).
Conversely, in patients undergoing retropubic prostatectomy
in a double-blind, randomized, placebo-controlled, dose-esca-
lation trial, treatment with rFVIIa significantly reduced perioper-
ative blood loss and the number of patients requiring
transfusions [60]. This study, in 36 patients, showed that
patients treated with either 20 or 40 µg/kg rFVIIa in the early
operative phase experienced significantly reduced periopera-
tive blood loss compared with those in the placebo group.
Furthermore, no patients in the higher-dose group required
transfusions, compared with 7 out of 12 placebo-treated
patients. The odds ratio for receiving any blood product in
patients treated with recombinant factor VIIa compared with
control patients was 0 (95% confidence interval 0.00 to 0.33).
However, although this study was randomized, double blind
and placebo controlled, the authors were aware of whether the
administered dose was 20 or 40 µg/kg.
The differences in the results observed in these two studies
might have occurred for several reasons, such as the age of
the patients enrolled in the two studies, and the type and loca-
tion of the surgery undergone. In addition, the timing of the
administration in the two studies might have influenced the
outcome. Patients received rFVIIa before the first incision in
the study by Raobaikady and colleagues [59] but much later in
the procedure in the study by Friederich and colleagues [60].
Given the relatively short half-life of rFVIIa, this might account
for some of the difference in efficacy observed in the two
studies.
Although there might be some beneficial effect on blood loss,
the committee felt that, on the balance of current evidence,
prophylactic use is not recommended.
Liver surgery
Recommendation. Prophylactic administration of rFVIIa during
orthotopic liver transplantation (OLT) or liver resection is not
recommended. Grade B
Rationale. Several studies have examined the effect of rFVIIa
in liver surgery. An early single-center safety study showed that
patients receiving 80 µg/kg before OLT required fewer trans-
fusions than matched historical controls [61], whereas in
these same patients it was shown that rFVIIa enhanced
thrombin generation in a localized, time-dependent manner
and did not lead to systemic activation of coagulation or fibri-
nolysis [62].
A larger multicenter, placebo-controlled trial examined the
effects of a single dose of rFVIIa (20, 40, or 80 µg/kg) admin-
istered immediately before surgery in 82 patients undergoing
OLT as a result of chronic liver disease [63]. This study failed
to show any effect on the primary endpoint, RBC transfusion
requirements, between placebo-treated and rFVIIa-treated
patients. There were also no significant differences between
treatment groups in the requirement for other transfusion prod-
ucts, total blood loss, crystalloid and colloid replacement vol-
ume, and the requirement for other hemostatic drugs during
the perioperative period.
A subsequent randomized, placebo-controlled study in 183
patients undergoing OLT as a result of cirrhosis (Child–Tur-
cotte–Pugh class B or C) used higher rFVIIa doses (60 and
120 µg/kg) or placebo repeated every 2 hours perioperatively
[64]. This study also failed to show any significant differences
between placebo and rFVIIa in perioperative RBC transfusionCritical Care    Vol 10 No 4    Vincent et al.
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requirements, the primary endpoint, although significantly
more rFVIIa-treated patients avoided RBC transfusions than
the placebo group (6 out of 62 in the 60 µg/kg group versus
0 out of 61 in the placebo group; p = 0.03). There were also
no significant differences in the requirement for any other
transfusion products, including FFP, platelet concentrate, and
fibrinogen [64]. Furthermore, compared with placebo, rFVIIa
failed to show any benefits on overall blood loss, the require-
ments for crystalloid or colloid replacement, or length of stay
in hospital or on the intensive care unit.
In a randomized, placebo-controlled study, 204 noncirrhotic
patients undergoing liver resection received 20 or 80 µg/kg
rFVIIa [65]. No significant reduction was observed in RBC
requirements, blood loss, or the number of patients
transfused.
Monitoring
Recommendation. No specific method is currently available to
indicate the need for rFVIIa or to monitor its efficacy. Monitor-
ing of rFVIIa efficacy should therefore be performed visually to
assess the level of bleeding after rFVIIa administration, and by
an assessment of the transfusion requirements after dosing.
Grade E
Rationale. Current laboratory tests are unlikely to provide an
accurate reflection of the condition of the patient because of
the time required to obtain the results. In many cases, samples
taken for analysis are rewarmed to 37°C before assay, and
this, together with the use of buffer solutions in laboratory
tests, fails to reflect the coagulation status of patients who are
acidotic or hypothermic. PT has been used to monitor rFVIIa
activity, but this measure often overestimates the effects of
rFVIIa because of its high sensitivity. The most accurate meas-
ure for monitoring the efficacy of rFVIIa is therefore to assess
bleeding visually. If the bleeding has stopped, no further rFVIIa
administration is required. The authors of several case studies
and case series have commented on the immediate visible




Absolute. rFVIIa should not be administered to patients who
are unsalvageable according to the clinical evaluation of the
medical team treating the patient.
Relative. The risk:benefit ratio should be assessed in patients
with coronary artery syndrome and in those with a presence or
history of thromboembolic events. Unstable coronary plaques
present TF on their surface [17]. Treatment with rFVIIa may
promote coagulation on these plaques, leading to acute com-
plete coronary artery occlusion or myocardial infarction
[66,67]. In addition, rFVIIa should not be administered to
patients with hypersensitivity to mouse, hamster, or bovine
proteins. As a consequence of the manufacturing process,
rFVIIa may contain traces of hamster proteins (the host cell
used to propagate the cloned DNA), mouse proteins (specifi-
cally, immunoglobulin G from immunoaffinity purification col-
umns), and bovine proteins (from the cell culture media).
Safety
Karkouti and colleagues observed an increased frequency of
acute renal failure in cardiac surgery patients receiving rFVIIa
[53]. However, thromboembolic adverse events after rFVIIa
administration cause the greatest concern, particularly in
patients with a previous history of thromboembolic events. An
increased incidence of thromboembolic adverse events may
arise as a result of systemic activation of the coagulation
pathway.
A recent systematic review of all published studies and case
series detailing rFVIIa use in nonhemophilia patients with
severe bleeding estimated that the incidence of thromboem-
bolic events was between 1% and 2% [68]. Data from the US
Food and Drug Administration Adverse Event Reporting Sys-
tem concerning reports of serious thromboembolic adverse
events during approved and off-label use of rFVIIa between
March 1999 and December 2004 record some 431 adverse
events, of which 168 reports described thromboembolic
events [69]. The authors state that reports to the US Food and
Drug Administration often lacked sufficient information to eval-
uate potential dosage associations, and that analysis of the
relationship between adverse events and rFVIIa was hindered
by concomitant medications, pre-existing medical conditions
and the confounding indication; the authors also note that ran-
domized, controlled trials are needed to establish the safety of
rFVIIa in patients without hemophilia. Many clinical trials have
shown no increase in thromboembolic events with rFVIIa in
comparison with placebo [28,59,60,64,65]. However, there is
uncertainty about thromboembolic events in patients with risk
factors for such events and in those with arterial disease, in
whom atherosclerotic plaques may expose TF and lead to the
activation of coagulation at sites other than the site of injury.
A nonsignificant increase in thromboembolic events was
observed in a recent trial of rFVIIa in patients with intracerebral
hemorrhage [70]. This trend was observed only in the sub-
group of patients receiving the highest rFVIIa dose (160 µg/
kg). Because patients with intracerebral hemorrhage have a
low bleeding rate, the clearance and half-life of rFVIIa is not
markedly decreased, as it is in trauma patients with severe
bleeding. It is therefore possible that administration of a very
high dose might have resulted in very high blood concentra-
tions. Given that rFVIIa has demonstrated a good safety profile
in other studies, this observation may suggest that high doses
in patients without severe bleeding might induce some
adverse events in either future trials and/or clinical use.Available online http://ccforum.com/content/10/4/R120
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Few data are available concerning the potential interactions
between rFVIIa and other drugs used to treat coagulopathy –
for example, aprotinin and desmopressin. Although instances
have been reported in trauma and cardiac surgery patients
[58] with no noticeable complications, caution is needed
because the number of cases reported is too low for any valid
conclusions to be drawn. The committee considers that the
administration of these drugs before treatment with rFVIIa
should not be considered as a contraindication for rFVIIa
administration in coagulopathic patients. Furthermore, if rFVIIa
has already been administered, there is no reason to recom-
mend the administration of other drugs to treat coagulopathy.
However, if rFVIIa is administered in addition to other agents,
the physician should monitor the patient closely for possible
thromboembolic adverse events.
Summary and future directions
The purpose of these guidelines is to summarize the current
evidence supporting the use of rFVIIa in the treatment of
uncontrolled hemorrhage, and offer some guidance on appro-
priate use (see Figure 1). Some countries have developed
local guidelines or consensus recommendations (for example,
the recently published consensus recommendations on off-
label use of rFVIIa by a US panel [71]), but European Union-
wide standardized guidance (appropriate dose, timing of treat-
ment, appropriate patients) is clearly needed. From the evi-
dence presented from case series and clinical studies
examining a wide variety of doses in patients with coagulopa-
thy resulting from a range of causes, it is possible to draw
some conclusions. However, it must be remembered that
there is a potential for significant publication bias in many of
the reported case studies and case series used to derive the
recommendations presented here.
First, there is a rationale for the use of rFVIIa to treat uncon-
trolled hemorrhage in certain indications. However, rFVIIa
should be used only as an adjunctive therapy to surgical con-
trol (and/or embolization), and only when all other attempts to
control bleeding have failed. Second, treatment with rFVIIa
seems to have some beneficial effect on blood loss and there-
fore on transfusion requirements. The risks of blood transfu-
sions have been well documented [11] and should generally
be avoided. In situations where transfusions are unavailable, or
are judged to be too risky, treatment with rFVIIa is acceptable
if death is the likely outcome of withholding rFVIIa treatment.
Third, rFVIIa is generally well tolerated, with a good safety pro-
file and relatively few thromboembolic events.
However, these positives should be balanced with some cave-
ats. Although benefits have been observed with regard to
blood loss and transfusion, there is currently no evidence to
suggest that this effect translates to an improvement in mor-
bidity or mortality. Furthermore, although current tolerability
data are favorable, further study is required to establish
whether certain patients are more at risk of thromboembolic
(or other) adverse events, and which pre-existing risk factors
need to be accounted for before administration. Finally, to
make definitive recommendations for use, data from prospec-
tive, randomized, controlled, blinded clinical trials are required.
Many of the data used to derive these recommendations come
from large case series, which limits the strength of the recom-
mendations that can be made. This is reflected in the grading
score of each recommendation. The process of developing
these guidelines and identifying where supporting evidence is
weak has therefore identified future directions for research
into rFVIIa, some of which are already being addressed by
ongoing clinical trials.
Conclusion
In response to a clinical need for practical guidance on the use
of rFVIIa in the management of uncontrolled massive hemor-
rhage, consensus guidelines have been developed by an
expert panel on the basis of a systematic review of the current
evidence base. There is grade B evidence to support the use
of rFVIIa, adjunctive to surgical control of bleeding, to manage
bleeding due to blunt trauma, grade E evidence of a possible
role for this therapy in the control of post-partum hemorrhage
and grades E and D evidence, respectively, for the use of
rFVIIa in the management of uncontrolled bleeding associated
with surgery and cardiac surgery. At present, a paucity of data
from randomized controlled trials with rFVIIa limits both the
strength and the scope of clinical recommendations.
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